Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production

Acta Pharmacologica Sinica

Volumn 31, Issue 7, 2010, Pages 839-848

  Liu, Qiong ^a   Wang, Xu ^a   Zhang, Yu ^a   Li, Chen Jing ^a   Hu, Li Hong ^a   Shen, Xu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Akt; carbon tetrachloride; collagen; hepatic stellate cells; Leukamenin F; liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; LEUKAMENIN F; MESSENGER RNA; NATURAL PRODUCT; PROTEIN KINASE B; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; DITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; IMAGE ANALYSIS; IN VIVO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER CIRRHOSIS; METABOLISM; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; TOXICITY;

ACTINS; ANIMALS; CARBON TETRACHLORIDE; CELL PROLIFERATION; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77954486525     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.64     Document Type: Article

References (36)

1. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fbrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005; 45: 605-628
2. Albanis E, Friedman SL. Hepatic fbrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-334, v-vi.
3. Bataller R, Brenner DA. Liver fbrosis. J Clin Invest 2005; 115: 209-218
4. Friedman SL. Molecular regulation of hepatic fbrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250
5. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2: 760-768
6. Marra F, Gentilini A, Pinzani M, Choudhury GG, Parola M, Herbst H, et al. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology 1997; 112: 1297-1306
7. Memmott RM, Dennis PA. Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal 2009; 21: 656-664
8. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168
9. Gabele E, Reif S, Tsukada S, Bataller R, Yata Y, Morris T, et al. The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem 2005; 280: 13374-13382
10. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fbrogenesis. Gut 2007; 56: 284-292
11. Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol 2000; 15 Suppl: D84-90.
12. Sun HD, Huang SX, Han QB. Diterpenoids from Isodon species and their biological activities. Nat Prod Rep 2006; 23: 673-698
13. Xu YL, Sun XC, Sun HD, Lin ZW, Wang DZ. Chemical structures of glaucocalyxin A and B. Acta Botan Yunnan 1981; 3: 283-286
14. Zhao Y, Huang SX, Yang LB, Pu JX, Xiao WL, Li LM, et al. Cytotoxic ent-kaurane diterpenoids from Isodon henryi. Planta Med 2009; 75: 65-69
15. 3H]-PAF binding. Thromb Haemost 1992; 67: 458-460
16. 4-caused injury and fbrogenesis by attenuating oxida-tive stress and suppressing infammation. Mol Pharmacol 2008; 73: 399-409.
17. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fbrosis. Nat Med 2006; 12: 671-676
18. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anan-damide induces necrosis in primary hepatic stellate cells. Hepatology 2005; 41: 1085-1095
19. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fbrosis. Gut 2005; 54: 142-151
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112
21. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specifc inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006; 69: 597-607.
22. 4 and adequate model of human cirrhosis? Hepatology 1983; 3: 112-120
23. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
24. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316
25. Friedman SL. Mechanisms of hepatic fbrogenesis. Gastroenterology 2008; 134: 1655-1669
26. Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A, et al. The role of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem 2003; 278: 8083-8090
27. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997; 410: 78-82.
28. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853-5857
29. Stuart CA, Howell ME, Baker JD, Dykes RJ, Duffourc MM, Ramsey MW, et al. Cycle training increased GLUT4 and activation of mammalian target of rapamycin in fast twitch muscle fbers. Med Sci Sports Exerc 2010; 42: 96-106.
30. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Muller B, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009; 135: 933-941
31. Sun X, Zhang X, Hu H, Lu Y, Chen J, Yasuda K, et al. Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fbro-sis. Biol Pharm Bull 2009; 32: 1533-1537
32. Friedman SL, Roll FJ, Boyles J, Arenson DM, Bissell DM. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 1989; 264: 10756-10762
33. Fayard E, Tintignac LA, Baudry A, Hemmings BA. Protein kinase B/Akt at a glance. J Cell Sci 2005; 118: 5675-5678
34. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654
35. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 1997; 272: 27678-27685
36. Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrubias-Pinedo A, et al. Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta- dependent mechanism in rat hepatic stellate cells. Hepatology 1999; 29: 960-970